Compare LFMD & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | CERS |
|---|---|---|
| Founded | 1994 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.5M | 276.0M |
| IPO Year | N/A | 1997 |
| Metric | LFMD | CERS |
|---|---|---|
| Price | $3.50 | $2.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $10.22 | $4.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $250,091,814.00 | $199,191,000.00 |
| Revenue This Year | $13.65 | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.78 | 13.03 |
| 52 Week Low | $3.43 | $1.12 |
| 52 Week High | $15.84 | $2.24 |
| Indicator | LFMD | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 73.96 |
| Support Level | $3.43 | $1.71 |
| Resistance Level | $3.84 | $1.78 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 5.18 | 91.06 |
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.